Minimization of potential hERG liability in histamine H3 receptor antagonists.
Black
L A
LA
Abbott Laboratories, GPRD Neuroscience Research, R4MN, AP9A-216, 100 Abbott Park Road, Abbott Park, IL 60064-6123, USA. larry.a.black@abbott.com
Liu
H
H
Diaz
G J
GJ
Fox
G B
GB
Browman
K E
KE
Wetter
J
J
Marsh
K C
KC
Miller
T R
TR
Esbenshade
T A
TA
Brioni
J
J
Cowart
M D
MD
D000818:Animals; D001522:Behavior, Animal; D001572:Benzofurans / Q000737:chemistry; D003503:Cyclobutanes / Q000737:chemistry; D054828:Histamine H3 Antagonists / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008297:Male; D015394:Molecular Structure; D009281:Naphthalenes / Q000737:chemistry; D011869:Radioligand Assay; D051381:Rats; D018100:Receptors, Histamine H3 / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D000071230:Transcriptional Regulator ERG
D001572:Benzofurans; D003503:Cyclobutanes; C072312:ERG protein, human; D054828:Histamine H3 Antagonists; D009281:Naphthalenes; D018100:Receptors, Histamine H3; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; C031721:naphthalene; C105430:benzofuran